An overview of current pharmacotherapy in perennial rhinitis.
BACKGROUND
Individuals with rhinitis experience significant morbidity due to their disease. Research and clinical care to reduce this suffering are important.


OBJECTIVE
To review the pharmacological agents that have been developed for the treatment of perennial rhinitis.


METHODS
Literature review of human studies.


RESULTS
Medication classes include antihistamines, decongestants, anticholinergics, cromolyn sodium, and corticosteroids. These vary in regard to their pharmacology, efficacy, and adverse effects. Compliance and cost issues are also critical components of the therapeutic regimen.


CONCLUSIONS
Carefully chosen pharmacotherapy based on an understanding of the pathophysiology of the disease, knowledge of the potential of medications, and commitment to an ongoing patient/physician education and monitoring program can lead to improved well-being for individuals with perennial rhinitis.
Meltzer
E O
EO
Allergy and Asthma Medical Group and Research Center, San Diego, CA 92123, USA.
D018680:Cholinergic Antagonists / Q000191:economics / Q000627:therapeutic use; D004205:Cromolyn Sodium / Q000191:economics / Q000627:therapeutic use; D005938:Glucocorticoids / Q000191:economics / Q000627:therapeutic use; D006634:Histamine H1 Antagonists / Q000191:economics / Q000627:therapeutic use; D006801:Humans; D014663:Nasal Decongestants / Q000191:economics / Q000627:therapeutic use; D010349:Patient Compliance; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy* / Q000191:economics
D018680:Cholinergic Antagonists; D005938:Glucocorticoids; D006634:Histamine H1 Antagonists; D014663:Nasal Decongestants; D004205:Cromolyn Sodium